JP2023542608A5 - - Google Patents
Info
- Publication number
- JP2023542608A5 JP2023542608A5 JP2023507542A JP2023507542A JP2023542608A5 JP 2023542608 A5 JP2023542608 A5 JP 2023542608A5 JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023507542 A JP2023507542 A JP 2023507542A JP 2023542608 A5 JP2023542608 A5 JP 2023542608A5
- Authority
- JP
- Japan
- Prior art keywords
- prostate cancer
- subject
- antagonist
- composition according
- glucocorticoid receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061013P | 2020-08-04 | 2020-08-04 | |
| US63/061,013 | 2020-08-04 | ||
| US202163226102P | 2021-07-27 | 2021-07-27 | |
| US63/226,102 | 2021-07-27 | ||
| PCT/US2021/044255 WO2022031642A2 (en) | 2020-08-04 | 2021-08-03 | Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542608A JP2023542608A (ja) | 2023-10-11 |
| JP2023542608A5 true JP2023542608A5 (https=) | 2024-07-30 |
Family
ID=80118471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507542A Pending JP2023542608A (ja) | 2020-08-04 | 2021-08-03 | グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230302014A1 (https=) |
| EP (1) | EP4192460A4 (https=) |
| JP (1) | JP2023542608A (https=) |
| CN (1) | CN116322694A (https=) |
| WO (1) | WO2022031642A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| WO2024006527A1 (en) * | 2022-07-01 | 2024-01-04 | Arvinas Operations, Inc. | Breast cancer treatment method |
| JP2025530798A (ja) * | 2022-09-02 | 2025-09-17 | コーセプト セラピューティクス， インコーポレイテッド | エキシコリラントとエンザルタミドを用いて前立腺がんを治療する方法 |
| WO2024092195A1 (en) * | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| WO2024220926A1 (en) * | 2023-04-21 | 2024-10-24 | Arvinas Operations, Inc. | Use of an androgen receptor degrader protac for the treatment of prostate cancer |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108699102A (zh) * | 2015-12-23 | 2018-10-23 | 欧瑞克制药公司 | 糖皮质激素受体抑制剂 |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| EP3793541A4 (en) * | 2018-05-16 | 2022-03-02 | GTx, Inc. | ANDROGEN RECEPTOR DEGRADER (SARD) SELECTIVE LIGANDS AND METHODS OF USE THEREOF |
-
2021
- 2021-08-03 JP JP2023507542A patent/JP2023542608A/ja active Pending
- 2021-08-03 WO PCT/US2021/044255 patent/WO2022031642A2/en not_active Ceased
- 2021-08-03 EP EP21852221.7A patent/EP4192460A4/en not_active Withdrawn
- 2021-08-03 CN CN202180068343.XA patent/CN116322694A/zh active Pending
- 2021-08-03 US US18/007,369 patent/US20230302014A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542608A5 (https=) | ||
| Lacal et al. | Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors | |
| JP2023098947A5 (https=) | ||
| JP2020516646A5 (https=) | ||
| JP7141408B2 (ja) | 前立腺癌の併用療法 | |
| JP2019510832A5 (https=) | ||
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2019503365A5 (https=) | ||
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| JP2018513123A5 (https=) | ||
| JP2022500479A5 (https=) | ||
| JP2019526632A5 (https=) | ||
| JP2022501383A5 (https=) | ||
| US12318386B2 (en) | Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer | |
| EP4218820A2 (en) | Combination therapies for the treatment of breast cancer | |
| JP7665700B2 (ja) | 肝細胞癌の治療のための併用療法 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP2022058873A5 (https=) | ||
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| TW202227068A (zh) | 組合藥物療法 | |
| CN110464845A (zh) | 一种用于乳腺癌免疫治疗的联合用药物组合及其应用 | |
| JP2023514056A5 (https=) | ||
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2025508944A5 (https=) | ||
| JP2017502989A5 (https=) |